RESEARCH PAPER
Prevalence of behavioral risk factors in people with HIV/AIDS and its’ effect on adherence to treatment
1
Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
2
Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
3
Research Center for Environmental Determinants of Health, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
Submission date: 2021-01-21
Final revision date: 2021-12-05
Acceptance date: 2021-12-25
Publication date: 2022-04-26
HIV & AIDS Review 2022;21(2):99-108
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Behavioral risk factors, in addition to increasing the risk of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) transmission, can affect antiretroviral therapy (ART) compliance of people with the condition. The aim of this study was to determine the prevalence of behavioral risk factors and its’ effect on adherence to antiretroviral drugs (ARV) treatment in patients with HIV/AIDS in Western Iran.
Material and methods:
This study was performed among all patients diagnosed with HIV/AIDS in Kermanshah Province for 25 years, from 1995 till 2019. Adherence to treatment in these patients was divided into three categories according to the World Health Organization definition, i.e., non-adherence, cessation, and adherence to treatment. Using single-variable and multi-variable logistic regression, the effect of important variables in four models was modified, and the effect of each of behavioral risk factors was analyzed in patients with non-adherence or experienced cessation compared to those who adhered to ARV.
Results:
Of the 2,867 patients with HIV/AIDS, 2,449 (85.42%) were males. The mean age of HIV infection was 33.36 ± 11.8 years. In 1995, less than 10 percent of people received treatment, and in 2019, it was more than 67 percent. All behavioral risk factors increased non-adherence to medication and cessation of ARV. In general, after controlling confounding variables, except for needle sharing, all behavioral variables affected ARV treatment. The greatest impact on non-adherence to medication was history of drug abuse, history of imprisonment, history of injection drug use, and sex with non-spouse, with a chance of 10.87 (range, 7.21-16.39), 3.94 (range, 2.84-5.46), 3.86 (range, 2.47-6.03), and 3.38 (range, 2.19-5.23) times more than patients without these risk factors, respectively.
Conclusions:
Although the process of receiving treatment has been increasing since 2005, the non-adherence to medication is still high in high-risk groups; therefore it is important to focus more on reducing non-adherence and eventual cessation of treatment. In particular, more attention is necessary for health education and raising the level of awareness of these groups.
Behavioral risk factors, in addition to increasing the risk of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) transmission, can affect antiretroviral therapy (ART) compliance of people with the condition. The aim of this study was to determine the prevalence of behavioral risk factors and its’ effect on adherence to antiretroviral drugs (ARV) treatment in patients with HIV/AIDS in Western Iran.
Material and methods:
This study was performed among all patients diagnosed with HIV/AIDS in Kermanshah Province for 25 years, from 1995 till 2019. Adherence to treatment in these patients was divided into three categories according to the World Health Organization definition, i.e., non-adherence, cessation, and adherence to treatment. Using single-variable and multi-variable logistic regression, the effect of important variables in four models was modified, and the effect of each of behavioral risk factors was analyzed in patients with non-adherence or experienced cessation compared to those who adhered to ARV.
Results:
Of the 2,867 patients with HIV/AIDS, 2,449 (85.42%) were males. The mean age of HIV infection was 33.36 ± 11.8 years. In 1995, less than 10 percent of people received treatment, and in 2019, it was more than 67 percent. All behavioral risk factors increased non-adherence to medication and cessation of ARV. In general, after controlling confounding variables, except for needle sharing, all behavioral variables affected ARV treatment. The greatest impact on non-adherence to medication was history of drug abuse, history of imprisonment, history of injection drug use, and sex with non-spouse, with a chance of 10.87 (range, 7.21-16.39), 3.94 (range, 2.84-5.46), 3.86 (range, 2.47-6.03), and 3.38 (range, 2.19-5.23) times more than patients without these risk factors, respectively.
Conclusions:
Although the process of receiving treatment has been increasing since 2005, the non-adherence to medication is still high in high-risk groups; therefore it is important to focus more on reducing non-adherence and eventual cessation of treatment. In particular, more attention is necessary for health education and raising the level of awareness of these groups.
REFERENCES (32)
1.
Global H. AIDS statistics – 2018 fact sheet. UNAIDS website unaids org/en/resources/fact-sheet (Accessed: 31.05.2019).
2.
Webb Mazinyo E, Kim L, Masuku S, Lancaster JL, Odendaal R, Uys M, et al. Adherence to concurrent tuberculosis treatment and antiretroviral treatment among co-infected persons in South Africa, 2008–2010. PLoS One 2016; 11: e0159317.
3.
Mohammadi Y, Mirzaei M, Shirmohammadi-Khorram N, Farhadian M. Identifying risk factors for late HIV diagnosis and survival analysis of people living with HIV/AIDS in Iran (1987-2016). BMC Infect Dis 2021; 21: 1-9.
4.
Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel. JAMA 2008; 300: 555-570.
5.
Davis A, Sarsembayeva L, Gulyaev V, Primbetova S, Terlikbayeva A, Mergenova G, et al. If you build it, will they use it? Preferences for antiretroviral therapy (ART) adherence monitoring among people who inject drugs (PWID) in Kazakhstan. AIDS Behav 2019; 23: 3294-3305.
6.
Organization WH. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision: World Health Organization; 2010.
7.
Yuan Y, L’italien G, Mukherjee J, Iloeje U. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV‐infected patient cohort. HIV Med 2006; 7: 156-162.
8.
Hamzeh B, Moradi Z, Najafi F, Moradinazar M. Pattern of substance abuse and prevalence of risk factors of HIV and hepatitis among addicted women in western Iran. Int J Prev Med 2019; 10.
9.
Tyndall MW, McNally M, Lai C, Zhang R, Wood E, Kerr T, et al. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J Drug Policy 2007; 18: 281-287.
10.
WHO. Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. World Health Organization; 2017.
11.
Antiretroviral Treatment. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015.
12.
Zali MR, Mehr AJ, Rezaian M, Meamar AR, Vaziri S, Mohraz M. Prevalence of intestinal parasitic pathogens among HIV-positive individuals in Iran. Jpn J Infect Dis 2004; 57: 268-270.
13.
Sabaté E, Sabaté E. Adherence to long-term therapies: evidence for action: World Health Organization; 2003.
14.
Association WM. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bulletin of the World Health Organization 2001; 79: 373.
15.
Reif S, Pence BW, Hall I, Hu X, Whetten K, Wilson E. HIV diagnoses, prevalence and outcomes in nine southern states. J Commun Health 2015; 40: 642-651.
16.
King W, Minor P, Kitchen CR, Ore L, Shoptaw S, Victorianne G, et al. Racial, gender and geographic disparities of antiretroviral treatment among US Medicaid enrolees in 1998. J Epidemiol Commun Health 2008; 62: 798-803.
17.
Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. JAIDS J Acquir Immune Def Syndr 2006; 42: 554-561.
18.
Monforte AdA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14: 499-507.
19.
Gant Z, Bradley H, Hu X, Skarbinski J, Hall HI, Lansky A. Hispanics or Latinos living with diagnosed HIV: progress along the continuum of HIV care – United States, 2010. MMWR Morb Mortality Weekly Rep 2014; 63: 886.
20.
Kazeroni PA, Gouya MM, Tira M, Sargolzaiie M, Eybpoosh S, Majdfar Z, et al. Prevention of Mother-to-Child Transmission (PMTCT) of HIV in Iran: Situation Analysis of the Pilot Phase. 2020.
21.
Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J General Internal Medicine 1999; 14: 267-273.
22.
Okonko I, Okerentuga P, Akinpelu A. Prevalence of HIV among attendees of ARFH centre in Ibadan, Southwestern Nigeria. Middle East J Sci Res 2012; 11: 7-12.
23.
Stark K, Herrmann U, Ehrhardt S, Bienzle U. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. Epidemiol Infect 2006; 134: 814-819.
24.
Palepu A, Tyndall MW, Chan K, Wood E, Montaner J, Hogg RS. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antiviral Ther 2004; 9: 713-720.
25.
Tucker JS, Burnam MA, Sherbourne CD, Kung F-Y, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003; 114: 573-580.
26.
McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, et al. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two US clinic cohorts. PLoS One 2011; 6: e18462.
27.
Marcellin F, Bonono C-R, Blanche J, Carrieri MP, Spire B, Koulla-Shiro S, et al. Higher risk of unsafe sex and impaired quality of life among patients not receiving antiretroviral therapy in Cameroon: results from the EVAL survey (ANRS 12-116). AIDS 2010; 24: S17-S25.
28.
Tassiopoulos K, Moscicki A-B, Mellins C, Kacanek D, Malee K, Allison S, et al. Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention development. Clin Infect Dis 2013; 56: 283-290.
29.
Secretariat NAC. Islamic Republic of Iran AIDS Progress Report. Ministry of Health and Medical Education Tehran; 2015.
30.
Sopheab H, Chhea C, Tuot S, Muir JA. HIV prevalence, related risk behaviors, and correlates of HIV infection among people who use drugs in Cambodia. BMC Infect Dis 2018; 18: 562.
31.
Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV AIDS Rep 2011; 8: 223.
32.
Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Preference and Adherence 2019; 13: 475.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
